Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) filed this Current Report on Form 8-K on August 12, 2021. The filing serves to announce the company's results of operations for the third quarter of fiscal 2021.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this filing. The document solely references the issuance of the Q3 2021 results press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are enumerated in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 12, 2021) for actual Q3 2021 financial figures.
- Verify the specific revenue and net loss numbers for the third quarter of fiscal 2021.
- Check the press release for any updates on clinical trial progress or product development milestones.
- Confirm the company's cash position and runway as disclosed in the referenced press release.